Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | LMNA | P02545 | 9/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salubrinal SCHEMBL6477826 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| Salubrinal SCHEMBL17360638 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL14782069 | 0.91 | MEN1 (0.84) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL21237547 | 0.89 | MEN1 (0.81) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL14819076 | 0.88 | MEN1 (0.78) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL16283211 | 0.88 | KMT2A (0.78) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL14819072 | 0.86 | MEN1 (0.75) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL17508602 | 0.86 | MEN1 (0.75) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL20438010 | 0.83 | MEN1 (0.72) | MEN1KMT2AMAPTHPGDALDH1A1 | |
| SCHEMBL28574843 | 0.81 | MEN1 (0.68) | MEN1KMT2AMAPTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118161473-A | ISRIB application in preparing medicine for preventing and treating ischemic cerebral apoplexy | 苏州大学 | 2024-06-11 | — | — | CN | claimed |
| EP-3820471-A1 | TREATMENT OF CHRONIC TRAUMATIC ENCEPHALOPATHY | CTEC LLC (US) | 2021-05-19 | — | — | EP | claimed |
| US-6946474-B2 | Nitrogen-containing compounds and their use as glycine transport inhibitors | MERCK & CO., INC. (US) | 2005-09-20 | — | — | US | claimed |
| JP-2004518628-A | — | — | 2004-06-24 | — | — | JP | claimed |
| US-20040034069-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | claimed |
| EP-1324986-A1 | NITROGEN-CONTAINING COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | GLIATECH, INC. (US) | 2003-07-09 | — | — | EP | claimed |
| US-20020082283-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | GLIATECH, INC. | 2002-06-27 | — | — | US | claimed |
| WO-2002022581-A1 | NITROGEN-CONTAINING COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | GLIATECH, INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-12157728-B2 | Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-12-03 | — | — | US | disclosed |
| CN-118161473-A | ISRIB application in preparing medicine for preventing and treating ischemic cerebral apoplexy | 苏州大学 | 2024-06-11 | — | — | CN | disclosed |
| US-20230382890-A1 | TARGETING OF ENDOPLASMIC RETICULUM DYSFUNCTION AND PROTEIN FOLDING STRESS TO TREAT NEUROLOGICAL CONDITIONS | ALS THERAPY DEVELOPMENT INSTITUTE | 2023-11-30 | — | — | US | disclosed |
| US-11708349-B2 | Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| CN-116397028-A | Application of copper death-related lncRNAs in lung squamous cell carcinoma prognosis evaluation | 桂林医学院 | 2023-07-07 | — | — | CN | disclosed |
| EP-3820471-A1 | TREATMENT OF CHRONIC TRAUMATIC ENCEPHALOPATHY | CTEC LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-2012140208-A1 | SCREENING METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-10-18 | — | — | WO | disclosed |
| US-6946474-B2 | Nitrogen-containing compounds and their use as glycine transport inhibitors | MERCK & CO., INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040034069-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | MERCK SHARP & DOHME CORP. | 2004-02-19 | — | — | US | disclosed |
| EP-1324986-A1 | NITROGEN-CONTAINING COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | GLIATECH, INC. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20020082283-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | GLIATECH, INC. | 2002-06-27 | — | — | US | disclosed |
| WO-2002022581-A1 | NITROGEN-CONTAINING COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | GLIATECH, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082283-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | SLC1A5, SLC6A7, SLC6A15 | MEN1 1992/4885KMT2A 4212/4885MAPT 1381/4885 |
| US-20230382890-A1 | TARGETING OF ENDOPLASMIC RETICULUM DYSFUNCTION AND PROTEIN FOLDING STRESS TO TREAT NEUROLOGICAL CONDITIONS | HSPA5, HSP90B1, HSPD1 | MEN1 4712/4885KMT2A 4807/4885MAPT 10/4885 |
| US-11708349-B2 | Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions | HSPA5, HSP90B1, HSPD1 | MEN1 4712/4885KMT2A 4807/4885MAPT 10/4885 |
| US-20040034069-A1 | Nitrogen-containing compounds and their use as glycine transport inhibitors | SLC1A5, SLC6A7, SLC6A15 | MEN1 1992/4885KMT2A 4212/4885MAPT 1381/4885 |
| US-12157728-B2 | Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions | HSPA5, HSP90B1, HSPD1 | MEN1 4712/4885KMT2A 4807/4885MAPT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.